<DOC>
	<DOC>NCT00434148</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.</brief_summary>
	<brief_title>Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease</brief_title>
	<detailed_description />
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Inclusion criteria 18 years or greater Confirmed diagnosis of ACTHdependent Cushing's disease Not considered candidate for pituitary surgery Exclusion criteria History of pituitary irradiation in the last 10 years Cushing's syndrome not caused by pituitary tumor Patients with active malignant disease (cancer) in the last 5 years Women who are pregnant or lactating Other protocoldefined inclusion/exclusion criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cushing's Disease</keyword>
	<keyword>pasireotide</keyword>
	<keyword>SOM230</keyword>
</DOC>